- Poster presentation
- Open Access
And yet... what makes the difference?
BMC Infectious Diseasesvolume 13, Article number: P21 (2013)
In the era of HAART C neoformans meningitis remains one of the most important opportunistic infections associated with HIV infection, with a high mortality (35-65%).
We present 3 cases of C neoformans meningitis occurred in immunocompromised patients with advanced HIV infection (CD4<50 cells/cmm) caused by strains with susceptibility to fluconazole dose-dependent and different clinical course.
The first case: a 28 years old patient, confirmed with HIV infection in 2009. He is diagnosed with systemic infection with C neoformans with pneumonia, meningitis and cutaneous cryptococcosis and a CD4<50 cells/cmm. Blood and CSF cultures were positive for C neoformans. CSF changes were minimal, but with high pressure. Was treated with fluconazole - 1200 mg/day and lumbar punctures were performed repeatedly. CSF cultures were negative with difficulty, after about 8 weeks of treatment. The evolution was unfavorable with neurocognitive deterioration, seizures and death.
The second case: a 24 years old patient, diagnosed with HIV infection in childhood, with a history of multiple antiretroviral regimens but with discontinued treatment two years ago is diagnosed with C neoformans meningitis and a CD4<50 cells/cmm. CSF changes were minimal and CSF pressure was increased. Under treatment with liposomal amphotericin and lumbar punctures at 2-3 days intervals the evolution was slowly favorable. After 8 weeks of antifungal therapy the antiretroviral treatment has been resumed.
The third case: a 54 years old patient with confirmed HIV infection in 2011 is diagnosed with C neoformans meningitis and a CD4<50 cells/cmm. CSF had significant changes with incresed cellularity and low glycorrachia. Treated with fluconazole – 1200 mg/day plus flucytosine – the evolution was favorable.
We discussed the different factors that determine the clinical course of C neoformans infection in HIV-infected patients with advanced immunosuppression.